Plain-English translation of NCT03832361 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called mirvetuximab soravtansine () to see if it can help women whose uterine cancer has come back or continues despite previous treatment. The medication is designed to find and attack cancer cells that have a specific protein marker on their surface. Researchers want to learn whether this new treatment is safe and effective for this type of cancer.
Women with recurrent or persistent uterine cancer often have limited treatment options, and many available therapies don't work well enough. This medication is designed to be more precise by targeting cancer cells with a specific protein, potentially offering a better option for patients who need new treatments.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of the medication once every 3 weeks at a hospital or clinic until the cancer progresses or you experience unacceptable side effects. During the study, you will have regular medical visits to check your health, blood tests to monitor how your body is responding, and imaging scans to measure whether your cancer is shrinking. The study will also collect information about your symptoms and side effects to help researchers understand how safe and effective this medication is.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Alessandro Santin
Collaborators
ImmunoGen, Inc., AbbVie
Enrollment target
~50 participants
Started
July 2020
Primary completion
October 2026
Age range
18 Years – 100 Years
Sex
Female only
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Alessandro D. Santin, M.D.
Yale University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.